Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease

A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and b...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-09, Vol.16 (9), p.1278
Main Authors: Hussain, Rafaqat, Khan, Shoaib, Ullah, Hayat, Ali, Farhan, Khan, Yousaf, Sardar, Asma, Iqbal, Rashid, Ataya, Farid S, El-Sabbagh, Nasser M, Batiha, Gaber El-Saber
Format: Article
Language:English
Subjects:
AChE
Alzheimer's disease
benzimidazole
Benzimidazoles
BuChE and molecular docking
Drug therapy
Drugs
Enzymes
Proteins
SAR
Schiff base
Schiff bases
synthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143
cites cdi_FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143
container_end_page
container_issue 9
container_start_page 1278
container_title Pharmaceuticals (Basel, Switzerland)
container_volume 16
creator Hussain, Rafaqat
Khan, Shoaib
Ullah, Hayat
Ali, Farhan
Khan, Yousaf
Sardar, Asma
Iqbal, Rashid
Ataya, Farid S
El-Sabbagh, Nasser M
Batiha, Gaber El-Saber
description A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). All these derivatives showed significant inhibition against AChE with an IC50 value in the range of 123.9 ± 10.20 to 342.60 ± 10.60 µM and BuChE in the range of 131.30 ± 9.70 to 375.80 ± 12.80 µM in comparison with standard Donepezil, which has IC50 values of 243.76 ± 5.70 µM (AChE) and 276.60 ± 6.50 µM (BuChE), respectively. Compounds 3, 5 and 9 exhibited potent inhibition against both AChE and BuChE. Molecular docking studies were used to validate and establish the structure–activity relationship of the synthesized derivatives.
doi_str_mv 10.3390/ph16091278
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_64dc6acef9a143fdb10b7920db70606b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771807276</galeid><doaj_id>oai_doaj_org_article_64dc6acef9a143fdb10b7920db70606b</doaj_id><sourcerecordid>A771807276</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143</originalsourceid><addsrcrecordid>eNptks9u1DAQxiMEoqVw4QkscUFIKbYT_wkXtO0WWqkIJMrZcpxx1qskTu2kUveAeI2-Hk-Cl62gi5AP9oy_7zea0WTZS4KPi6LCb8cV4bgiVMhH2SEpaZlLWorHD94H2bMY1xgzQUryNDsohOAMS3mYfT-BYeN61-iN7yA_0REa9NWsnLVoG6Dz2zq4bUpb67smvkML9CX43kU3tGgxjsFrs0KTR0u4gc6P6NPcTS6_0qGFCS3D3EZkfUCLbrMC10P4-eMuoqWLkPDPsydWdxFe3N9H2bcPZ1en5_nl548Xp4vL3DAiplyWFEtuuDXaQGFrXUupSUMt00xjSy2xpRYUc2pKzkQBFISUIAtdUmJJWRxlFztu4_VajcH1Otwqr536nfChVTpMznSgeNkYnsrYSiejbWqCa1FR3NQCc8zrxHq_Y41z3UNjYJiC7vag-z-DW6nW3yiCWcEKIhPh9T0h-OsZ4qTSOA10nR7Az1FRKTApqrKiSfrqH-naz2FIs0oqXjHKOHuganXqwA3Wp8JmC1ULIYjEggqeVMf_UaXTQO-MH8C6lN8zvNkZTPAxBrB_miRYbVdP_V294hc7Wsou</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869525652</pqid></control><display><type>article</type><title>Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Hussain, Rafaqat ; Khan, Shoaib ; Ullah, Hayat ; Ali, Farhan ; Khan, Yousaf ; Sardar, Asma ; Iqbal, Rashid ; Ataya, Farid S ; El-Sabbagh, Nasser M ; Batiha, Gaber El-Saber</creator><creatorcontrib>Hussain, Rafaqat ; Khan, Shoaib ; Ullah, Hayat ; Ali, Farhan ; Khan, Yousaf ; Sardar, Asma ; Iqbal, Rashid ; Ataya, Farid S ; El-Sabbagh, Nasser M ; Batiha, Gaber El-Saber</creatorcontrib><description>A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). All these derivatives showed significant inhibition against AChE with an IC50 value in the range of 123.9 ± 10.20 to 342.60 ± 10.60 µM and BuChE in the range of 131.30 ± 9.70 to 375.80 ± 12.80 µM in comparison with standard Donepezil, which has IC50 values of 243.76 ± 5.70 µM (AChE) and 276.60 ± 6.50 µM (BuChE), respectively. Compounds 3, 5 and 9 exhibited potent inhibition against both AChE and BuChE. Molecular docking studies were used to validate and establish the structure–activity relationship of the synthesized derivatives.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph16091278</identifier><identifier>PMID: 37765088</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>AChE ; Alzheimer's disease ; benzimidazole ; Benzimidazoles ; BuChE and molecular docking ; Drug therapy ; Drugs ; Enzymes ; Proteins ; SAR ; Schiff base ; Schiff bases ; synthesis</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2023-09, Vol.16 (9), p.1278</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143</citedby><cites>FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143</cites><orcidid>0000-0003-0473-889X ; 0000-0002-0981-7805 ; 0000-0003-3833-1457 ; 0000-0001-5404-0954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2869525652/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2869525652?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids></links><search><creatorcontrib>Hussain, Rafaqat</creatorcontrib><creatorcontrib>Khan, Shoaib</creatorcontrib><creatorcontrib>Ullah, Hayat</creatorcontrib><creatorcontrib>Ali, Farhan</creatorcontrib><creatorcontrib>Khan, Yousaf</creatorcontrib><creatorcontrib>Sardar, Asma</creatorcontrib><creatorcontrib>Iqbal, Rashid</creatorcontrib><creatorcontrib>Ataya, Farid S</creatorcontrib><creatorcontrib>El-Sabbagh, Nasser M</creatorcontrib><creatorcontrib>Batiha, Gaber El-Saber</creatorcontrib><title>Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease</title><title>Pharmaceuticals (Basel, Switzerland)</title><description>A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). All these derivatives showed significant inhibition against AChE with an IC50 value in the range of 123.9 ± 10.20 to 342.60 ± 10.60 µM and BuChE in the range of 131.30 ± 9.70 to 375.80 ± 12.80 µM in comparison with standard Donepezil, which has IC50 values of 243.76 ± 5.70 µM (AChE) and 276.60 ± 6.50 µM (BuChE), respectively. Compounds 3, 5 and 9 exhibited potent inhibition against both AChE and BuChE. Molecular docking studies were used to validate and establish the structure–activity relationship of the synthesized derivatives.</description><subject>AChE</subject><subject>Alzheimer's disease</subject><subject>benzimidazole</subject><subject>Benzimidazoles</subject><subject>BuChE and molecular docking</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Enzymes</subject><subject>Proteins</subject><subject>SAR</subject><subject>Schiff base</subject><subject>Schiff bases</subject><subject>synthesis</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks9u1DAQxiMEoqVw4QkscUFIKbYT_wkXtO0WWqkIJMrZcpxx1qskTu2kUveAeI2-Hk-Cl62gi5AP9oy_7zea0WTZS4KPi6LCb8cV4bgiVMhH2SEpaZlLWorHD94H2bMY1xgzQUryNDsohOAMS3mYfT-BYeN61-iN7yA_0REa9NWsnLVoG6Dz2zq4bUpb67smvkML9CX43kU3tGgxjsFrs0KTR0u4gc6P6NPcTS6_0qGFCS3D3EZkfUCLbrMC10P4-eMuoqWLkPDPsydWdxFe3N9H2bcPZ1en5_nl548Xp4vL3DAiplyWFEtuuDXaQGFrXUupSUMt00xjSy2xpRYUc2pKzkQBFISUIAtdUmJJWRxlFztu4_VajcH1Otwqr536nfChVTpMznSgeNkYnsrYSiejbWqCa1FR3NQCc8zrxHq_Y41z3UNjYJiC7vag-z-DW6nW3yiCWcEKIhPh9T0h-OsZ4qTSOA10nR7Az1FRKTApqrKiSfrqH-naz2FIs0oqXjHKOHuganXqwA3Wp8JmC1ULIYjEggqeVMf_UaXTQO-MH8C6lN8zvNkZTPAxBrB_miRYbVdP_V294hc7Wsou</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Hussain, Rafaqat</creator><creator>Khan, Shoaib</creator><creator>Ullah, Hayat</creator><creator>Ali, Farhan</creator><creator>Khan, Yousaf</creator><creator>Sardar, Asma</creator><creator>Iqbal, Rashid</creator><creator>Ataya, Farid S</creator><creator>El-Sabbagh, Nasser M</creator><creator>Batiha, Gaber El-Saber</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0473-889X</orcidid><orcidid>https://orcid.org/0000-0002-0981-7805</orcidid><orcidid>https://orcid.org/0000-0003-3833-1457</orcidid><orcidid>https://orcid.org/0000-0001-5404-0954</orcidid></search><sort><creationdate>20230901</creationdate><title>Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease</title><author>Hussain, Rafaqat ; Khan, Shoaib ; Ullah, Hayat ; Ali, Farhan ; Khan, Yousaf ; Sardar, Asma ; Iqbal, Rashid ; Ataya, Farid S ; El-Sabbagh, Nasser M ; Batiha, Gaber El-Saber</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>AChE</topic><topic>Alzheimer's disease</topic><topic>benzimidazole</topic><topic>Benzimidazoles</topic><topic>BuChE and molecular docking</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Enzymes</topic><topic>Proteins</topic><topic>SAR</topic><topic>Schiff base</topic><topic>Schiff bases</topic><topic>synthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hussain, Rafaqat</creatorcontrib><creatorcontrib>Khan, Shoaib</creatorcontrib><creatorcontrib>Ullah, Hayat</creatorcontrib><creatorcontrib>Ali, Farhan</creatorcontrib><creatorcontrib>Khan, Yousaf</creatorcontrib><creatorcontrib>Sardar, Asma</creatorcontrib><creatorcontrib>Iqbal, Rashid</creatorcontrib><creatorcontrib>Ataya, Farid S</creatorcontrib><creatorcontrib>El-Sabbagh, Nasser M</creatorcontrib><creatorcontrib>Batiha, Gaber El-Saber</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hussain, Rafaqat</au><au>Khan, Shoaib</au><au>Ullah, Hayat</au><au>Ali, Farhan</au><au>Khan, Yousaf</au><au>Sardar, Asma</au><au>Iqbal, Rashid</au><au>Ataya, Farid S</au><au>El-Sabbagh, Nasser M</au><au>Batiha, Gaber El-Saber</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>16</volume><issue>9</issue><spage>1278</spage><pages>1278-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). All these derivatives showed significant inhibition against AChE with an IC50 value in the range of 123.9 ± 10.20 to 342.60 ± 10.60 µM and BuChE in the range of 131.30 ± 9.70 to 375.80 ± 12.80 µM in comparison with standard Donepezil, which has IC50 values of 243.76 ± 5.70 µM (AChE) and 276.60 ± 6.50 µM (BuChE), respectively. Compounds 3, 5 and 9 exhibited potent inhibition against both AChE and BuChE. Molecular docking studies were used to validate and establish the structure–activity relationship of the synthesized derivatives.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37765088</pmid><doi>10.3390/ph16091278</doi><orcidid>https://orcid.org/0000-0003-0473-889X</orcidid><orcidid>https://orcid.org/0000-0002-0981-7805</orcidid><orcidid>https://orcid.org/0000-0003-3833-1457</orcidid><orcidid>https://orcid.org/0000-0001-5404-0954</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals (Basel, Switzerland), 2023-09, Vol.16 (9), p.1278
issn 1424-8247
1424-8247
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_64dc6acef9a143fdb10b7920db70606b
source Publicly Available Content (ProQuest); PubMed Central
subjects AChE
Alzheimer's disease
benzimidazole
Benzimidazoles
BuChE and molecular docking
Drug therapy
Drugs
Enzymes
Proteins
SAR
Schiff base
Schiff bases
synthesis
title Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer’s Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A22%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benzimidazole-Based%20Schiff%20Base%20Hybrid%20Scaffolds:%20A%20Promising%20Approach%20to%20Develop%20Multi-Target%20Drugs%20for%20Alzheimer%E2%80%99s%20Disease&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=Hussain,%20Rafaqat&rft.date=2023-09-01&rft.volume=16&rft.issue=9&rft.spage=1278&rft.pages=1278-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph16091278&rft_dat=%3Cgale_doaj_%3EA771807276%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c517t-842086c6fcace3fbab88a1d2f5a5a0f2f1f4a72062c46573e2e788e83a421f143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2869525652&rft_id=info:pmid/37765088&rft_galeid=A771807276&rfr_iscdi=true